STOCK TITAN

Deepening losses and heavy debt pressure OneMeta (ONEI) in Q1 2026

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
10-Q

Rhea-AI Filing Summary

OneMeta Inc. reported higher Q1 2026 revenue of $180,117, up from $128,518 a year earlier, but losses and leverage increased sharply. Operating expenses rose to $2.5 million, driven mainly by higher general and administrative and research and development spending, leading to a net loss of $3,306,954 versus $954,215.

Interest expense surged to $926,373 as the company added substantial convertible notes and promissory debt, including 14% secured instruments with attached warrants. Cash was $60,124 and the working capital deficit widened to $6,075,967, with current liabilities of $6,319,486 against total assets of $245,199.

Management states there is substantial doubt about OneMeta’s ability to continue as a going concern and is seeking additional debt and equity financing. Subsequent events include a $3,000,000 reseller prepayment, a $2,850,000 repurchase of Series B‑1 preferred shares, and a default on secured promissory notes that triggered issuance of 8,750,000 common shares. The company also reports material weaknesses in internal controls over financial reporting.

Positive

  • None.

Negative

  • Escalating losses and leverage: Q1 2026 net loss widened to $3,306,954 from $954,215, with interest expense jumping to $926,373 and current liabilities reaching $6,319,486 against total assets of $245,199.
  • Going concern uncertainty: Management states there is substantial doubt about OneMeta’s ability to continue as a going concern as of March 31, 2026, given recurring losses and a $6,075,967 working capital deficit.
  • Debt complexity and dilution risk: Significant 14% secured convertible notes, promissory notes with equity kickers, and share‑settled interest create high financing cost and potential dilution, including 9,650,000 warrants and 5,365,000 options outstanding.
  • Default and forced equity issuance: On April 7, 2026 the company defaulted on March 26, 2026 secured promissory notes, triggering issuance of 8,750,000 common shares to the holders.
  • Internal control weaknesses: Management concludes disclosure controls and internal control over financial reporting were ineffective as of December 31, 2025 and March 31, 2026, with multiple identified material weaknesses.

Insights

Revenue is growing modestly, but losses, leverage and control issues dominate the picture.

OneMeta increased Q1 2026 revenue to $180,117, but operating expenses of $2,500,442 and interest expense of $926,373 drove a net loss of $3,306,954. Current liabilities of $6,319,486 versus total assets of $245,199 highlight a strained balance sheet.

The filing details multiple layers of debt: $3,140,000 of convertible notes, $716,695 of promissory notes and significant related‑party convertible debt, much of it at double‑digit stated or effective rates, plus warrants and share‑settled interest. This structure materially increases financing costs and potential dilution.

Management explicitly discloses “substantial doubt” about the company’s ability to continue as a going concern as of March 31, 2026. Subsequent events compound this: default on March 26, 2026 secured notes led to issuance of 8,750,000 shares, while a $3,000,000 reseller prepayment and a $2,850,000 preferred repurchase significantly reshape liquidity and equity. Internal control weaknesses over financial reporting also persist from December 31, 2025.

Revenue $180,117 Three months ended March 31, 2026
Net loss $3,306,954 Three months ended March 31, 2026
Interest expense $926,373 Three months ended March 31, 2026
Working capital deficit $6,075,967 As of March 31, 2026
Cash balance $60,124 As of March 31, 2026
Convertible notes payable $3,140,000 Non‑related party, as of March 31, 2026
Promissory notes payable, net $716,695 As of March 31, 2026
Deferred revenue $303,624 As of March 31, 2026
going concern financial
"all of which raise substantial doubt about the Company’s ability to continue as a going concern."
A going concern is a business that is expected to continue its operations and meet its obligations for the foreseeable future, rather than shutting down or selling off assets. This assumption matters to investors because it indicates stability and ongoing profitability, making the business a more reliable investment. Think of it as believing a restaurant will stay open and serve customers, rather than closing down suddenly.
convertible notes payable financial
"As of March 31, 2026 and December 31, 2025, the convertible notes payable principal balance was $940,000 and $940,000, respectively"
A convertible notes payable is a company loan recorded as debt that can later be exchanged for shares of the company instead of being repaid in cash. Investors care because it affects both the company’s obligations and ownership: it temporarily increases debt on the balance sheet but can dilute existing shareholders if converted, much like an IOU that can either be paid back or traded in for a slice of the business.
debt discount financial
"The Company recognized amortization on the debt discount of $612,338 during the period ended March 31, 2026."
deferred revenue financial
"As of March 31, 2026, the deferred revenue balance was $140,500."
Cash a company has already received for goods or services it has promised but not yet delivered; it's recorded as a liability because the company still owes that product, service, or future revenue recognition. For investors, deferred revenue signals upcoming work or deliveries that will convert into reported sales over time and affects short-term obligations, cash flow quality, and how quickly a firm can grow recognized revenue—think of it like prepaid subscriptions or gift cards a business must honor later.
stock-based compensation financial
"During the three months ended March 31, 2026, the Company recognized $106,555 of expense related to outstanding stock options."
Stock-based compensation is when a company pays employees, directors or consultants with shares or the right to buy shares instead of or in addition to cash. It matters to investors because issuing stock or options spreads ownership thinner (like cutting a pie into more slices), which can reduce each existing share’s claim on profits and can also change reported earnings; investors watch it to assess true cost of running the business and how management is incentivized.
material weakness financial
"we determined that there were control deficiencies that constituted material weaknesses which are indicative of many small companies"
A material weakness is a significant flaw in the systems and checks a company uses to ensure its financial reports are accurate, meaning errors or fraud could happen and not be caught. For investors it matters because it raises the risk that reported results are unreliable—similar to finding a hole in a ship’s hull—potentially leading to corrected financials, regulatory action, reduced trust, and negative effects on stock value and borrowing costs.
false --12-31 Q1 0001388295 0001388295 2026-01-01 2026-03-31 0001388295 2026-05-15 0001388295 2026-03-31 0001388295 2025-12-31 0001388295 us-gaap:NonrelatedPartyMember 2026-03-31 0001388295 us-gaap:NonrelatedPartyMember 2025-12-31 0001388295 us-gaap:RelatedPartyMember 2026-03-31 0001388295 us-gaap:RelatedPartyMember 2025-12-31 0001388295 us-gaap:SeriesAPreferredStockMember 2026-03-31 0001388295 us-gaap:SeriesAPreferredStockMember 2025-12-31 0001388295 ONEI:SeriesBOnePreferredStockMember 2026-03-31 0001388295 ONEI:SeriesBOnePreferredStockMember 2025-12-31 0001388295 2025-01-01 2025-03-31 0001388295 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-12-31 0001388295 us-gaap:PreferredStockMember ONEI:SeriesBOnePreferredStockMember 2024-12-31 0001388295 us-gaap:CommonStockMember 2024-12-31 0001388295 ONEI:CommonStockLiabilityMember 2024-12-31 0001388295 ONEI:SeriesBOneConvertiblePreferredStockLiabilityMember 2024-12-31 0001388295 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001388295 us-gaap:RetainedEarningsMember 2024-12-31 0001388295 2024-12-31 0001388295 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-12-31 0001388295 us-gaap:PreferredStockMember ONEI:SeriesBOnePreferredStockMember 2025-12-31 0001388295 us-gaap:CommonStockMember 2025-12-31 0001388295 ONEI:CommonStockLiabilityMember 2025-12-31 0001388295 ONEI:SeriesBOneConvertiblePreferredStockLiabilityMember 2025-12-31 0001388295 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001388295 us-gaap:RetainedEarningsMember 2025-12-31 0001388295 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-01-01 2025-03-31 0001388295 us-gaap:PreferredStockMember ONEI:SeriesBOnePreferredStockMember 2025-01-01 2025-03-31 0001388295 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001388295 ONEI:CommonStockLiabilityMember 2025-01-01 2025-03-31 0001388295 ONEI:SeriesBOneConvertiblePreferredStockLiabilityMember 2025-01-01 2025-03-31 0001388295 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001388295 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001388295 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2026-01-01 2026-03-31 0001388295 us-gaap:PreferredStockMember ONEI:SeriesBOnePreferredStockMember 2026-01-01 2026-03-31 0001388295 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001388295 ONEI:CommonStockLiabilityMember 2026-01-01 2026-03-31 0001388295 ONEI:SeriesBOneConvertiblePreferredStockLiabilityMember 2026-01-01 2026-03-31 0001388295 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001388295 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001388295 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-03-31 0001388295 us-gaap:PreferredStockMember ONEI:SeriesBOnePreferredStockMember 2025-03-31 0001388295 us-gaap:CommonStockMember 2025-03-31 0001388295 ONEI:CommonStockLiabilityMember 2025-03-31 0001388295 ONEI:SeriesBOneConvertiblePreferredStockLiabilityMember 2025-03-31 0001388295 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001388295 us-gaap:RetainedEarningsMember 2025-03-31 0001388295 2025-03-31 0001388295 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2026-03-31 0001388295 us-gaap:PreferredStockMember ONEI:SeriesBOnePreferredStockMember 2026-03-31 0001388295 us-gaap:CommonStockMember 2026-03-31 0001388295 ONEI:CommonStockLiabilityMember 2026-03-31 0001388295 ONEI:SeriesBOneConvertiblePreferredStockLiabilityMember 2026-03-31 0001388295 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001388295 us-gaap:RetainedEarningsMember 2026-03-31 0001388295 ONEI:OEMAgreementMember 2024-10-08 0001388295 ONEI:OEMAgreementMember 2025-01-01 2025-12-31 0001388295 ONEI:OEMAgreementMember 2026-01-01 2026-03-31 0001388295 ONEI:OEMAgreementMember 2026-03-31 0001388295 us-gaap:WarrantMember 2026-01-01 2026-03-31 0001388295 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-03-31 0001388295 ONEI:SeriesBOnePreferredStockMember 2026-01-01 2026-03-31 0001388295 us-gaap:SeriesAPreferredStockMember 2026-01-01 2026-03-31 0001388295 us-gaap:ConvertibleNotesPayableMember 2026-01-01 2026-03-31 0001388295 ONEI:SubscriptionLicenseAndSoftwareRevenueMember 2026-01-01 2026-03-31 0001388295 ONEI:SubscriptionLicenseAndSoftwareRevenueMember 2025-01-01 2025-03-31 0001388295 ONEI:ProfessionalServicesMember 2026-01-01 2026-03-31 0001388295 ONEI:ProfessionalServicesMember 2025-01-01 2025-03-31 0001388295 ONEI:OEMSolutionMember 2026-01-01 2026-03-31 0001388295 ONEI:OEMSolutionMember 2025-01-01 2025-03-31 0001388295 ONEI:RowlandDayMember ONEI:FormerChiefFinancialOfficerMember 2026-01-01 2026-03-31 0001388295 ONEI:RowlandDayMember ONEI:FormerChiefFinancialOfficerMember 2025-01-01 2025-03-31 0001388295 ONEI:RowlandDayMember ONEI:FormerChiefFinancialOfficerMember 2026-03-31 0001388295 ONEI:RowlandDayMember ONEI:FormerChiefFinancialOfficerMember 2025-12-31 0001388295 ONEI:SaulLealMember srt:ChiefExecutiveOfficerMember 2026-01-01 2026-03-31 0001388295 ONEI:SaulLealMember srt:ChiefExecutiveOfficerMember 2025-01-01 2025-03-31 0001388295 ONEI:SaulLealMember srt:ChiefExecutiveOfficerMember 2026-03-31 0001388295 ONEI:SaulLealMember srt:ChiefExecutiveOfficerMember 2025-12-31 0001388295 srt:ChiefExecutiveOfficerMember 2026-02-02 2026-02-02 0001388295 srt:ChiefExecutiveOfficerMember 2026-02-02 0001388295 srt:ChiefExecutiveOfficerMember 2026-03-31 0001388295 ONEI:PromissoryNoteAgreementMember srt:DirectorMember 2026-01-27 0001388295 ONEI:PromissoryNoteAgreementMember srt:DirectorMember 2026-02-01 2026-02-01 0001388295 ONEI:PromissoryNoteAgreementMember srt:DirectorMember 2026-03-31 0001388295 ONEI:RowlandDayMember ONEI:SeniorSecuredPromissoryNotesPayableMember 2025-01-01 2025-12-31 0001388295 ONEI:RowlandDayMember ONEI:SeniorSecuredPromissoryNotesPayableMember 2024-01-01 2024-12-31 0001388295 ONEI:RowlandDayMember ONEI:SeniorSecuredPromissoryNotesPayableMember 2025-12-31 0001388295 ONEI:RowlandDayMember ONEI:SeniorSecuredPromissoryNotesPayableMember 2024-12-31 0001388295 ONEI:RowlandDayMember ONEI:SeniorSecuredPromissoryNotesPayableMember 2026-03-31 0001388295 ONEI:RowlandDayMember 2025-10-31 2025-10-31 0001388295 ONEI:SeriesBOnePreferredStockMember ONEI:RowlandDayMember 2025-10-31 0001388295 ONEI:RowlandDayMember us-gaap:CommonStockMember 2025-10-31 0001388295 ONEI:SeriesBOnePreferredStockMember ONEI:RowlandDayMember srt:MinimumMember 2025-10-31 0001388295 ONEI:SeriesBOnePreferredStockMember ONEI:RowlandDayMember srt:MaximumMember 2025-10-31 0001388295 us-gaap:CommonStockMember ONEI:RowlandDayMember srt:MinimumMember 2025-10-31 0001388295 us-gaap:CommonStockMember ONEI:RowlandDayMember srt:MaximumMember 2025-10-31 0001388295 ONEI:RowlandDayMember 2026-03-26 2026-03-26 0001388295 ONEI:RowlandDayMember 2026-01-01 2026-03-31 0001388295 ONEI:RowlandDayMember 2026-03-31 0001388295 ONEI:RowlandDayMember 2026-03-26 0001388295 us-gaap:ConvertibleNotesPayableMember srt:DirectorMember 2026-03-31 0001388295 us-gaap:ConvertibleNotesPayableMember srt:DirectorMember 2025-12-31 0001388295 us-gaap:ConvertibleNotesPayableMember srt:DirectorMember 2026-01-01 2026-03-31 0001388295 us-gaap:ConvertibleNotesPayableMember srt:DirectorMember 2025-01-01 2025-12-31 0001388295 us-gaap:ConvertibleNotesPayableMember srt:DirectorMember 2026-03-31 0001388295 us-gaap:ConvertibleNotesPayableMember srt:DirectorMember 2025-12-31 0001388295 2025-12-25 0001388295 ONEI:ThreeInvestorsMember us-gaap:ConvertibleNotesPayableMember 2024-12-01 2024-12-31 0001388295 ONEI:ThreeInvestorsMember us-gaap:ConvertibleNotesPayableMember 2025-12-31 0001388295 ONEI:ThreeInvestorsMember us-gaap:ConvertibleNotesPayableMember 2025-01-01 2025-12-31 0001388295 us-gaap:ConvertibleNotesPayableMember 2026-03-31 0001388295 us-gaap:ConvertibleNotesPayableMember 2026-01-01 2026-03-31 0001388295 us-gaap:ConvertibleNotesPayableMember 2025-12-31 0001388295 ONEI:PurchaseAgreementsMember 2025-10-31 2025-10-31 0001388295 ONEI:PurchaseAgreementsMember 2025-10-31 0001388295 srt:MaximumMember ONEI:PurchaseAgreementsMember 2025-10-31 2025-10-31 0001388295 srt:MinimumMember ONEI:PurchaseAgreementsMember 2025-10-31 2025-10-31 0001388295 ONEI:TwoPromissoryNoteAgreementsMember 2026-02-11 0001388295 ONEI:TwoPromissoryNoteAgreementsMember 2026-02-11 2026-02-11 0001388295 ONEI:TwoPromissoryNoteAgreementsMember ONEI:ThreeMonthsThereafterMember 2026-02-11 2026-02-11 0001388295 ONEI:PromissoryNoteOneMember 2025-09-11 2025-09-11 0001388295 ONEI:PromissoryNoteOneMember 2025-09-11 0001388295 ONEI:PromissoryNoteOneMember 2026-01-01 2026-03-31 0001388295 ONEI:PromissoryNoteOneMember 2026-03-31 0001388295 ONEI:PromissoryNoteOneMember 2025-12-31 0001388295 ONEI:PromissoryNoteTwoMember 2025-10-13 2025-10-13 0001388295 ONEI:PromissoryNoteTwoMember 2025-10-13 0001388295 ONEI:PromissoryNoteTwoMember 2026-01-01 2026-03-31 0001388295 ONEI:PromissoryNoteTwoMember 2026-03-31 0001388295 ONEI:PromissoryNoteTwoMember 2025-12-31 0001388295 ONEI:SecuredPromissoryNoteAgreementsMember ONEI:TwoInvestorsMember 2026-03-26 0001388295 ONEI:SecuredPromissoryNoteAgreementsMember ONEI:TwoInvestorsMember 2026-03-26 2026-03-26 0001388295 ONEI:SecuredPromissoryNoteAgreementsMember ONEI:TwoInvestorsMember 2026-01-01 2026-03-31 0001388295 ONEI:SecuredPromissoryNoteAgreementsMember ONEI:TwoInvestorsMember 2026-03-31 0001388295 ONEI:PromissoryNoteMember 2026-03-31 0001388295 ONEI:PromissoryNoteMember 2025-12-31 0001388295 ONEI:SeriesAConvertiblePreferredStockMember 2026-03-31 0001388295 ONEI:SeriesAConvertiblePreferredStockMember 2026-01-01 2026-03-31 0001388295 ONEI:SeriesAConvertiblePreferredStockMember 2025-12-31 0001388295 ONEI:SeriesBOnePreferredStockMember 2026-01-01 2026-03-31 0001388295 ONEI:SeriesBOnePreferredStockMember 2023-09-30 2023-09-30 0001388295 srt:ChiefExecutiveOfficerMember ONEI:SeriesBOnePreferredStockMember 2026-03-09 2026-03-09 0001388295 ONEI:SeriesBOnePreferredStockMember 2026-03-09 0001388295 ONEI:SeriesBOnePreferredStockMember 2026-03-09 2026-03-09 0001388295 ONEI:SeriesBTwoPreferredStockMember 2026-03-31 0001388295 ONEI:SeriesBTwoPreferredStockMember 2025-12-31 0001388295 ONEI:ConvertiblePromissoryNotesMember 2026-01-01 2026-03-31 0001388295 ONEI:ConvertiblePromissoryNotesMember 2026-03-31 0001388295 ONEI:AccountsPayableSettlementMember 2026-01-01 2026-03-31 0001388295 ONEI:AccountsPayableSettlementMember 2026-03-31 0001388295 ONEI:ConsultantMember 2026-01-01 2026-03-31 0001388295 ONEI:SeveralConsultantAgreementsMember 2026-01-01 2026-03-31 0001388295 ONEI:ConsultantAgreementOneMember 2026-01-01 2026-01-01 0001388295 ONEI:ConsultantAgreementOneMember 2026-01-01 2026-03-31 0001388295 ONEI:SixMonthTermConsultantAgreementMember 2025-12-18 2025-12-18 0001388295 ONEI:SixMonthTermConsultantAgreementMember 2026-01-01 2026-03-31 0001388295 ONEI:ConsultantAgreementTwoMember 2025-08-01 2025-08-01 0001388295 ONEI:ConsultantAgreementTwoMember 2025-12-15 2025-12-15 0001388295 ONEI:ConsultantAgreementTwoMember 2025-01-01 2025-12-31 0001388295 ONEI:ConsultantAgreementTwoMember 2026-01-01 2026-03-31 0001388295 ONEI:ConsultantAgreementThreeMember 2025-08-01 2025-08-01 0001388295 ONEI:ConsultantAgreementThreeMember 2025-01-01 2025-12-31 0001388295 ONEI:ConsultantAgreementThreeMember 2026-01-01 2026-03-31 0001388295 ONEI:SeveralConsultantAgreementsMember 2026-03-31 0001388295 ONEI:AdvisorOneMember 2026-03-30 2026-03-30 0001388295 ONEI:AdvisorOneMember 2026-01-01 2026-03-31 0001388295 ONEI:AdvisorTwoMember 2025-11-10 2025-11-10 0001388295 ONEI:AdvisorTwoMember 2026-01-01 2026-03-31 0001388295 ONEI:AdvisorThreeMember 2025-10-01 2025-10-01 0001388295 ONEI:AdvisorThreeMember 2026-01-01 2026-03-31 0001388295 ONEI:AdvisorFourMember 2024-12-01 2024-12-01 0001388295 ONEI:AdvisorFourMember 2026-01-01 2026-03-31 0001388295 us-gaap:WarrantMember 2026-01-01 2026-03-31 0001388295 us-gaap:EmployeeStockOptionMember ONEI:EmployeesMember 2026-02-23 2026-02-23 0001388295 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-03-31 0001388295 us-gaap:EmployeeStockOptionMember 2026-03-31 0001388295 us-gaap:MeasurementInputSharePriceMember us-gaap:WarrantMember 2026-03-31 0001388295 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2026-03-31 0001388295 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2026-03-31 0001388295 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:WarrantMember 2026-03-31 0001388295 us-gaap:MeasurementInputExpectedTermMember us-gaap:WarrantMember 2026-03-31 0001388295 us-gaap:WarrantMember 2025-12-31 0001388295 us-gaap:WarrantMember 2026-03-31 0001388295 us-gaap:MeasurementInputSharePriceMember us-gaap:EmployeeStockOptionMember 2026-03-31 0001388295 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:EmployeeStockOptionMember 2026-03-31 0001388295 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:EmployeeStockOptionMember 2026-03-31 0001388295 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:EmployeeStockOptionMember 2026-03-31 0001388295 us-gaap:MeasurementInputExpectedTermMember us-gaap:EmployeeStockOptionMember 2026-03-31 0001388295 us-gaap:EmployeeStockOptionMember 2025-12-31 0001388295 ONEI:ChiefExecutiveOfficerAndDirectorMember 2024-12-31 0001388295 us-gaap:SubsequentEventMember ONEI:MasterResellerAgreementMember 2026-04-08 0001388295 us-gaap:SubsequentEventMember ONEI:SeriesBOnePreferredStockMember ONEI:RowlandDayMember 2026-04-10 2026-04-10 0001388295 us-gaap:SubsequentEventMember ONEI:SeriesBOnePreferredStockMember ONEI:RowlandDayMember 2026-04-10 0001388295 us-gaap:SubsequentEventMember ONEI:SecuredPromissoryNotesMember 2026-04-07 2026-04-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure ONEI:Integer ONEI:Segment

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2026

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ________to ________.

 

Commission File Number 000-56565

 

ONEMETA INC.

(Exact name of registrant as specified in its charter)

 

Nevada   20-5150818

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

 

450 South 400 East, Suite 200, Bountiful, UT 84010

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (702) 550-0122

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of exchange on which registered
None.        

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated Filer ☐ Accelerated Filer ☐ Non-Accelerated Filer Smaller Reporting Company Emerging Growth Company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

As of May 15, 2026, the registrant had 38,890,943 shares of common stock outstanding.

 

 

 

 

 

 

TABLE OF CONTENTS

 

PART I. FINANCIAL INFORMATION 3
     
Item 1. Financial Statements (Unaudited) 3
     
  Balance Sheets 3
     
  Statements of Operations 4
     
  Statements of Changes in Stockholders’ Equity (Deficit) 5
     
  Statements of Cash Flows 6
     
  Notes to Financial Statements (Unaudited) 7
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 21
     
Item 4. Controls and Procedures 27
     
PART II. OTHER INFORMATION 28
     
Item 1. Legal Proceedings 28
     
Item 1A. Risk Factors 28
     
Item 6. Exhibits 28
     
SIGNATURES 29

 

2

 

 

PART I - FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

ONEMETA INC.

BALANCE SHEETS

 

   March 31, 2026   December 31, 2025 
   (Unaudited)     
ASSETS          
Current assets:          
Cash  $60,124   $4,584 
Accounts receivable, net   50,186    22,508 
Subscription receivable   50,000    - 
Prepaid and other current assets   83,209    94,845 
Total current assets   243,519    121,937 
           
Noncurrent Assets:          
Property and equipment, net   1,680    1,843 
Total noncurrent assets   1,680    1,843 
           
Total assets  $245,199   $123,780 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)          
Current liabilities:          
Accounts payable  $1,038,469   $926,889 
Accrued expenses   528,698    133,845 
Accrued expenses, related party   117,000    97,000 
Related party advances   25,000    - 
Convertible notes payable   3,140,000    940,000 
Convertible notes payable, related party   450,000    250,000 
Promissory notes payable, net   716,695    380,321 
Deferred revenue   303,624    316,196 
Total current liabilities   6,319,486    3,044,251 
           
Noncurrent Liabilities:          
Convertible notes payable, net of current portion and discount   -    1,387,612 
Total noncurrent liabilities   -    1,387,612 
           
Total liabilities   6,319,486    4,431,863 
           
STOCKHOLDERS’ EQUITY (DEFICIT)          
Preferred stock, $0.001 par value, 50,000,000 shares authorized,   -    - 
Series A preferred stock, $0.001 par value, 5,000,000 shares authorized, 2,068 issued and outstanding   2    2 
Series B-1 convertible preferred stock, $0.001 par value, 8,619,420 shares
authorized, 8,619,420 shares issued and outstanding
   862    862 
Common stock, $0.001 par value, 500,000,000 shares authorized,
38,890,943 and 38,890,943 shares issued and outstanding, respectively
   38,891    38,891 
Common stock liability   1,474,605    527,889 
Series B-1 convertible preferred stock liability   1,129,920    - 
Additional paid in capital   37,944,158    38,480,044 
Accumulated deficit   (46,662,725)   (43,355,771)
Total stockholders’ equity (deficit)   (6,074,287)   (4,308,083)
Total liabilities and stockholders’ equity (deficit)  $245,199   $123,780 

 

The accompanying notes are an integral part of these financial statements.

 

3

 

 

ONEMETA INC.

STATEMENTS OF OPERATIONS

(Unaudited)

 

   Three months ended   Three months ended 
   March 31, 2026   March 31, 2025 
         
Revenue  $180,117   $128,518 
Cost of revenue   65,560    - 
Gross profit   114,557    128,518 
           
Operating expenses:          
Research and development   406,311    349,586 
General and administrative   1,937,753    481,320 
Advertising and marketing   2,011    8,725 
Legal and professional   154,367    218,420 
Total operating expenses   2,500,442    1,058,051 
Loss from operations   (2,385,885)   (929,533)
           
Other income (expense):          
Other income   5,304    - 
Interest expense   (926,373)   (24,682)
Total other expense   (921,069)   (24,682)
Net loss  $(3,306,954)  $(954,215)
Net loss per common share:          
Basic  $(0.09)  $(0.03)
Diluted  $(0.09)  $(0.03)
           
Weighted average common shares outstanding:          
Basic   38,890,943    37,790,943 
Diluted   38,890,943    37,790,943 

 

The accompanying notes are an integral part of these unaudited financial statements.

 

4

 

 

ONEMETA INC.

STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)

For the three months ended March 31, 2026 and 2025

(Unaudited)

 

   Shares      Shares      Shares                   
   Series A Preferred Stock   Series B-1 Convertible Preferred Stock   Common Stock   Common Stock   Series B-1 Convertible Preferred Stock   Additional paid-in   Accumulated     
   Shares   Amount   Shares   Amount   Shares   Amount   liability   liability   capital  

Deficit

   Total 
Balance, December 31, 2024   2,068   $2    8,619,420   $862    37,790,943   $37,791   $-   $-   $36,792,679   $(39,516,154)   (2,684,820)
Stock based compensation   -    -    -    -    -    -    -    -    83,901    -    83,901 
Net loss   -    -    -    -    -    -    -    -    -    (954,215)   (954,215)
Balance, March 31, 2025   2,068   $2    8,619,420   $862    37,790,943   $37,791   $-   $-   $36,876,580   $(40,470,369)  $(3,555,134)
                                                        
Balance, December 31, 2025   2,068   $2    8,619,420   $862    38,890,943   $38,891   $527,889   $-   $38,480,044   $(43,355,771)  $(4,308,083)
Series B-1 Preferred stock repurchase deposit   -    -    -    -    -    -    -    -    (950,000)   -    (950,000)
Series B-1 Preferred stock liability   -    -    -    -    -    -    -    1,129,920    -    -    1,129,920 
Common shares liability   -    -    -    -    -    -    946,716    -    -    -    946,716 
Stock based compensation   -    -    -    -    -    -    -    -    130,557    -    130,557 
Imputed interest   -    -    -    -    -    -    -    -    30,723    -    30,723 
Relative fair value of warrants issued with convertible debt   -    -    -    -    -    -    -    -    252,834    -    252,834 
Net loss   -    -    -    -    -    -    -    -    -    (3,306,954)   (3,306,954)
Balance, March 31, 2026   2,068   $2    8,619,420   $862    38,890,943   $38,891   $1,474,605   $1,129,920   $37,944,158   $(46,662,725)   (6,074,287)

 

The accompanying notes are an integral part of these unaudited financial statements.

 

5

 

 

ONEMETA INC.

STATEMENTS OF CASH FLOWS

(Unaudited)

 

   Three Months ended   Three Months ended 
   March 31, 2026   March 31, 2025 
CASH FLOWS FROM OPERATING ACTIVITIES          
Net loss  $(3,306,954)  $(954,215)
Adjustment to reconcile net loss to cash used in operating activities:          
Imputed interest   30,723    - 
Stock based compensation    130,557    83,901 
Common stock liability   946,716    - 
Series B-1 Preferred stock liability    1,129,920    - 
Amortization of debt discount   688,678    - 
Depreciation expense    163    - 
Net change in:          
Accounts receivable    (27,678)   (38,550)
Subscription receivable   (50,000)   - 
Prepaid and other current assets    11,636    591 
Accounts payable   131,664    263,976 
Accrued expenses    294,853    43,040 
Accrued expenses, related party   (84)   74,682 
Deferred revenue    (12,572)   (90,000)
           
CASH FLOWS USED IN OPERATING ACTIVITIES   (32,378)   (616,575)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Proceeds from senior secured promissory notes, related party   -    9,000 
Payments of senior secured notes payable, related party   -    (6,000)
Proceeds from convertible notes   200,000    190,000 
Proceeds from convertible notes, related party    200,000    250,000 
Proceeds from promissory notes, related party   80,000      
Repayment of senior secured promissory notes   (80,000)   - 
Repayment of senior secured promissory notes   (187,082)   - 
Proceeds from related party advances    25,000    - 
Payment of Series B-1 Preferred stock repurchase   (150,000)   - 
           
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES   87,918    443,000 
           
NET CHANGE IN CASH   55,540    (173,575)
Cash, beginning of period    4,584    215,816 
Cash, end of period  $60,124   $42,241 
           
SUPPLEMENTAL CASH FLOW INFORMATION          
           
Cash paid on interest expense  $107,126   $42,526 
Cash paid for income taxes   $-   $- 
           
NON-CASH TRANSACTIONS           
Expenses paid on the Company’s behalf  $20,084   $82,529 
Series B-1 Preferred stock repurchased with a note   $700,000   $- 
Relative fair value of warrants issued with convertible debt  $252,834   $- 
Series B-1 repurchase costs  $100,000   $- 

 

The accompanying notes are an integral part of these financial statements.

 

6

 

 

OneMeta Inc.

(Formerly OneMeta AI)

Notes to the Financial Statements

(Unaudited)

 

Note 1. Basis of Presentation

 

The accompanying unaudited interim financial statements of OneMeta Inc. (“we”, “our”, “OneMeta” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission (“SEC”) and should be read in conjunction with the financial statements and notes thereto contained in the Company’s fiscal 2025 financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for our interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would substantially duplicate the disclosure contained in the financial statements for fiscal 2025, have been omitted.

 

OneMeta was originally incorporated as Promotions on Wheels Holdings, Inc., a Nevada corporation, on July 3, 2006. On December 26, 2008, the name of the Company was changed to Blindspot Alert, Inc. On September 11, 2009, the Company’s name was changed to WebSafety, Inc. On March 23, 2021, the Company’s name was changed to VeriDetx Corp. On June 8, 2021, the Company’s name was changed to WebSafety, Inc. On July 10, 2022, the Company’s name was changed to OneMeta AI. On June 20, 2023, the Company’s name was changed to OneMeta Inc.

 

Note 2. Summary of Significant Accounting Policies

 

Use of Estimates

 

In preparing financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates in the accompanying financial statements involving the valuation of stock-based compensation, fair value measurement and long-term customer contracts.

 

Cash and Cash Equivalents

 

Cash equivalents include all highly liquid investments with original maturities of three months or less.

 

Accounts Receivable

 

Accounts receivable are comprised of unsecured amounts due from customers. The Company carries its accounts receivable at their face amounts less an allowance for credit losses. The allowance for credit losses is recognized based on management’s estimate of likely losses per year, past experience, review of customer profiles and the aging of receivable balances. As of March 31, 2026 and December 31, 2025, there was $1,160 of allowance for credit losses.

 

Related Parties

 

The Company follows ASC 850, “Related Party Disclosures,” for the identification of related parties and disclosure of related party transactions.

 

Fair Value of Financial Instruments

 

The Company’s financial instruments consist primarily of cash and accounts payable. The carrying values of these financial instruments approximate their respective fair values as they are short-term in nature or carry interest rates that approximate market rates.

 

7

 

 

Revenue Recognition

 

The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts With Customers, which was adopted on January 1, 2018 using the modified retrospective method, with no impact to the Company’s comparative financial statements. Revenues are recognized when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration the Company expects to be entitled to in exchange for transferring those goods or services. Revenue is recognized based on the following five step model:

 

Identification of the contract with a customer
Identification of the performance obligations in the contract
Determination of the transaction price
Allocation of the transaction price to the performance obligations in the contract
Recognition of revenue when, or as, the Company satisfies a performance obligation

 

Subscription and license

 

We enter into revenue arrangements in which a customer may purchase a combination of subscriptions, consulting services, training and education. Fully hosted subscription services (“SaaS”) allow customers to access hosted software during the contractual term without taking possession of the software.

 

We recognize revenue ratably over the contractual service term for hosted services that are priced based on a committed number of transactions where the delivery and consumption of the benefit of the services occur evenly over time, beginning on the date the services associated with the committed transactions are first made available to the customer and continuing through the end of the contractual service term. Over-usage fees and fees based on the actual number of transactions are billed in accordance with contract terms as these fees are incurred and are included in the transaction price of an arrangement as variable consideration. Revenue based on per-minute or per-word basis, where invoicing is aligned to the pattern of performance, customer benefit and consumption, are typically accounted for utilizing the “as-invoiced” practical expedient. Revenue for subscriptions sold as a fee per period is recognized ratably over the contractual term as the customer simultaneously receives and consumes the benefit of the underlying service.

 

Licenses for software may be purchased as a subscription for a fixed period of time or based on usage. Revenue from licenses is recognized at the point in time the software is available to the customer, provided all other revenue recognition criteria are met, and classified as revenue on our Statements of Operations. Our interpretation or translation services fees are based on a per-minute or per-word basis, are typically accounted for utilizing the “as-invoiced” practical expedient.

 

Our services are comprised primarily of fees related to training, and education for certain licenses that are recognized at a point in time. Training and education revenues are recognized as the services are performed.

 

OEM solution

 

The Company provides Over-the-phone, consecutive AI Translation Service (“VerbumCall SDK”) that uses WebSocket connections to provide an AI service designed to facilitate effortless communication across languages within the platforms. This product leverages advanced AI capabilities to provide consecutive audio translation, ensuring that both patrons and agents experience conversations without the need for additional steps or complicated setups.

 

The Company has multiple performance obligations in the customer contract with inContact. The Company is to generate revenue through the following sources: sale of OEM Solution software and professional services, which consist of implementation, configuration, custom development, optimization, training and technical support services of the OEM Solution.

 

8

 

 

VerbumAgentis

 

On March 31, 2025, the Company entered into a reseller and distribution agreement to provide software development kit (SDK) to the reseller to use and/or resell to their customers. The Company will provide the reseller with a VerbumAgentis communication platform and an encryption key to install on their computer system and servers. In return, the reseller is to pay an initial one-time paid-up fee of $500,000.

 

VerbumAgentis is a standalone communication platform with core capabilities such as chat-based interaction, transcription, and multilingual simultaneous interpretation for voice-to-voice customer interactions. It includes real-time bidirectional communication and integrations. While live translation leverages underlying language models (SDK), the core platform delivers independent value even without SDK execution for each interaction.

 

VerbumAgentis is installed on client’s servers that they control. The Company is to deliver and install the VerbumAgentis platform on the customers’ server and provide translation services on an as requested basis by the end customers. The customer benefits from the VerbumAgentis platform as a standalone system once installed on their infrastructure. Further, the translation services and other per usage items outlined in the contract are obligations that arise when those services are initiated by the customer.

 

Disaggregation of revenues

 

The Company disaggregates revenue between subscription and license revenue and professional service revenue.

 

   Three Months
Ended
March 31, 2026
   Three Months
Ended
March 31, 2025
 
Subscription, license and software revenue  $755   $- 
Professional services   168,375    128,518 
OEM Solution usage   10,987    - 
Total revenue  $180,117   $128,518 

 

Deferred Revenue

 

Deferred revenue includes service and support contracts and represents the undelivered performance obligation of agreements that are typically for one year or less. On October 8, 2024, the Company entered into an OEM Agreement to provide OEM Solutions hosting consisting of over-the-phone consecutive AI language translation solutions. Upon execution of the agreement, the Company received $700,000 from NICE as a credit balance for future service. The Company identified three separate performance obligations within the contract. The performance obligations are OEM Solution service, professional services and technical support. The OEM Solution revenue is recognized based on a per-minute rate while the professional services and technical support revenue is recognized based on a per hour rate. The Company expects the $700,000 credit to be used mainly by OEM Solution and professional services. The Company recognized $448,804 of the credit during the year ended December 31, 2025. As of March 31, 2026, the Company expects to recognize all the unsatisfied performance obligations as revenue in the following quarter. During the three months ended March 31, 2026, the Company recognized $110,696 as revenue from the credit. As of March 31, 2026, the deferred revenue balance was $140,500.

 

During the period ended March 31, 2026, the Company recorded additional $98,125 of deferred revenue. As of March 31, 2026 and December 31, 2025, the deferred revenue balance was $303,624 and $316,196, respectively.

 

Stock-Based Compensation

 

All stock-based awards to employees and non-employee contractors, including any grants of stock and stock options, are measured at fair value at the grant date and recognized over the relevant vesting period in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 718. Stock based awards to non-employees are recognized as a selling, general and administrative expense over the period of performance. Such awards are measured at fair value at the date of grant. In addition, for awards that vest immediately, the awards are measured at fair value and recognized in full at the grant date.

 

9

 

 

Basic and Diluted Loss Per Share

 

Basic loss per common share is computed by dividing the net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is determined by using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of March 31, 2026, the Company’s potentially dilutive shares, which were not included in the calculation of net loss per share, included warrants to purchase 9,650,000 common shares, options to purchase 5,365,000 common shares, conversion of Series B-1 shares to purchase 94,813,620 common shares, conversion of Series A shares to purchase 2,585 common shares, and the conversion of the convertible notes to 34,338,135 common shares. Accordingly, the number of weighted average shares outstanding, as well as the amount of net loss per share are presented for basic and diluted per share calculations As of March 31, 2026 and 2025, reflected in the accompanying statement of operations.

 

Segments Reporting

 

The Company manages its operations as a single segment for the purpose of assessing performance and making operating decisions. The Company’s Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company using information about combined net income from operations. All significant operating decisions are based upon an analysis of the Company as one operating segment, which is the same as its reporting segment.

 

Recent Accounting Pronouncements

 

Disaggregation of Income Statement Expenses

 

In November 2024, the FASB issued Accounting Standards Update No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40) (“ASU 2024-03”). ASU 2024-03 requires specified information about certain costs and expenses be disclosed in the notes to the financial statements, including the expense caption on the face of the income statement in which they are disclosed, in addition to a qualitative description of remaining amounts not separately disaggregated. Entities will also be required to disclose their definition of “selling expenses” and the total amount in each annual period. The standard is effective for the Company for annual periods beginning January 1, 2027 and for interim periods beginning January 1, 2028, with updates applied either prospectively or retrospectively. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its disclosures.

 

Credit Losses

 

In July 2025, the FASB issued ASU 2025-05, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets, which provides updates related to CECL guidance for certain short-term receivables. The ASU is effective for fiscal years beginning after December 15, 2025. We adopted ASU No. 2025-05 during the year ended December 31, 2026, with no material impact to the Company’s financial statements or results of operations.

 

Note 3. Going Concern

 

These financial statements have been prepared in accordance with generally accepted accounting principles applicable to a going concern, which assumes that the Company will be able to meet its obligations and continue its operations for its next fiscal year. Realization values may be substantially different from carrying values as shown and these financial statements do not give effect to adjustments that would be necessary to the carrying values and classification of assets and liabilities should the Company be unable to continue as a going concern. As of March 31, 2026, the Company had not yet achieved profitable operations and expects to incur further losses in the development of its business, all of which raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon its ability to generate future profitable operations and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. The Company is actively seeking funding through debt and equity offerings. Management cannot be certain that such events or a combination thereof can be achieved.

 

10

 

 

Note 4. Related Party Transactions

 

Expense paid on the Company’s behalf

 

During the three months ended March 31, 2026 and 2025, former chief financial officer paid $0 and $82,529 of expenses on the Company’s behalf and was repaid $0 and $0, respectively. As of March 31, 2026 and December 31, 2025, the balance owed to former chief financial officer $0.

 

During the three months ended March 31, 2026 and 2025, the chief executive officer paid $20,084 and $0 of expenses on the Company’s behalf and was repaid $0 and $0, respectively. As of March 31, 2026 and December 31, 2025, the balance owed to chief executive officer $20,084 and $0, respectively.

 

Accruals

 

As of March 31, 2026, the accrued related party salary and accrued interest expense was $117,000 and $13,826, respectively. As of December 31, 2025, the accrued related party salary and accrued interest expense was $97,000 and $12,307, respectively.

 

During the period ended March 31, 2026, the board approved a health stipend for the Company’s Chief Executive Officer, Saul Leal, in the amount of $2,800 per month with a 5% cumulative interest on the unpaid balance. The stipend and interest were retroactively applied back to commencing of service in July 2022. As of March 31, 2026, the Company accrued $126,000 for the stipend and $12,792 for the accrued interest.

 

Advances

 

On February 2, 2026, the Company’s Chief Executive Officer advanced the Company $25,000 to be used for operating expenditures. The advance is due on demand and accrues interest at a rate of 14%. As of March 31, 2026, the advance and accrued interest balance was $25,000 and $547, respectively.

 

Secure promissory note

 

On January 27, 2026, the Company entered into a promissory note agreement for $80,000 with Roy Chestnutt, Company’s Director. The Company recognized debt discount of $1,612 at the issuance of the note. Pursuant to the agreement, the interest on the promissory note shall equal to 16,000 shares of restricted common stock of the Company. Both the principal balance and the shares are payable on February 1, 2026. As of February 1, 2026, the Company paid the principal balance of $80,000 and issued the 16,000 common shares for the accrued interest. As of March 31, 2026, the principal balance of the promissory note was $0. As of March 31, 2026, the common shares were not issued to the equity holders and as such, the common shares were recorded as common stock liability on the statement of stockholder’s equity.

 

During the years ended December 2025 and 2024, the Company entered into multiple secured promissory notes agreements with the Company’s former Chief Executive Officer, Rowland Day, for total proceeds of $883,500. The notes were secured by the assets of the Company and accrued interest at the rate of 14% per annum. During the year ended December 31, 2025 and as part of the separation agreement with Rowlan Day, the Company repaid the outstanding principal balance of $802,450 and the accrued interest of $101,225. As of March 31, 2026 and December 31, 2025, the related party senior secured promissory notes payable principal balance was $0 and $0, respectively, with accrued interest of $0 and $0, respectively.

 

11

 

 

Settlement Agreement

 

Effective October 31, 2025, Rowland W. Day II resigned from his positions as President, Chief Financial Officer, Secretary, Chief Legal Officer, and as a member of the Board of Directors of the Company. In connection with his resignation, the Company made payments to Mr. Day in the amount of $917,966 in satisfaction of outstanding loans and reimbursable credit card balances owed to him and a payment in the amount of $408,486 for accrued salary. In connection with his resignation, the Company agreed to enter into a Stock Repurchase Agreement providing for repurchase by the Company from the Trust of up to 4,309,710 shares of the Company’s Series B-1 Preferred Stock and 307,647 shares of common stock, at per-share prices ranging from $0.605-$0.66 for the preferred shares and $0.055-$0.06 for the common shares, depending on the repurchase date. The purchase was to occur on or around March 27, 2026 (the “Expiration Date”). On March 26, 2026, the Company entered into an amendment to the Stock Repurchase Agreement pursuant to which the Expiration Date was extended to April 10, 2026. As part of the extension of the settlement date, the Company is to pay an additional $100,000 to Rowland as an extension fee. During the period ended March 31, 2026, the Company accrued the $100,000 extension fee and paid $150,000 as a deposit on the stock re-purchase to Rowland. Additionally, through issuance of two notes dated March 26, 2026 (Note 6), $700,000 was wire directly by the noteholder to Rowland as a deposit on the stock re-purchase.

 

Convertible notes payable

 

During the year ended December 31, 2025 and the period ended March 31, 2026, the Company issued a series of 0% interest convertible notes payable to a director, a director nominee and two relatives of a the director nominee in exchange for $450,000. The convertible notes mature six months following that date of issuance and do not accrue interest. The notes are convertible into common shares as follows: (i) on the next equity financing conversion: the principal balance on each note will convert into shares upon the closing of the next equity financing. The number of conversion shares the Company issues upon such conversion will equal the quotient obtained by dividing (x) the outstanding principal balance under each converting note on the closing date of the next equity financing by (y) the applicable conversion price of the product of (x) 100% less the discount of 25% and (y) the lowest per share purchase price of the equity securities issued in the next equity financing; and/or (ii) corporate transaction conversion: at the closing of a major corporate transaction, the note will convert into that number of conversion shares equal to the quotient obtained by dividing (x) the outstanding principal balance of such note on the closing of such corporate transaction by (y) the applicable conversion price of the product of (x) 100% less the discount of 25% and (y) the volume weighted average trading price on the date that is ten days immediately prior to the closing date of the corporate transaction; and/or (iii) at any time on or after the maturity date, each note will convert into that number of conversion shares equal to the quotient obtained by dividing (x) the outstanding principal balance of the note on the date of such conversion by (y) the applicable conversion price of the product of (x) 100% less the discount of 25% and (y) the volume weighted average trading price on the date that is ten days immediately prior to the maturity date.

 

During the period ended March 31, 2026, the Company and four noteholders amended the terms of the convertible note agreements to retroactively accrue interest on their notes from the effective date of the agreements on a rate of 10%. During the period ended March 31, 2026, the Company recorded and accrued interest expense on the convertible notes in the amount of $22,726.

 

Company evaluated the conversion feature and determined that no embedded derivative liability existed on the issuance dates of the convertible notes. As of March 31, 2026 and December 31, 2025, the convertible notes payable principal balance was $450,000 and $250,000, respectively, and the accrued interest was $22,726 and $0, respectively. The Company calculated imputed interest on the zero percent convertible notes using an interest rate of 14% and recorded to additional paid-in-capital. As of March 31, 2026 and December 31, 2025, the Company recorded imputed interest of $3,414 and $30,359, respectively.

 

The Company evaluated the conversion feature and determined that, since the conversion price is fixed, no embedded derivative liability existed as of March 31, 2026. As March 31, 2026, the matured convertible notes would potentially be converted into 1,299,934 common shares.

 

   As of March 31, 2026   As of December 31, 2025 
         
Convertible notes payable, relate party  $450,000   $250,000 
Total convertible notes payable, relate party   450,000    250,000 
Less: current portion   (450,000)   (250,000)
Long term convertible notes payable, relate party, net of current  $-   $- 

 

12

 

 

Note 5. Convertible Notes Payable

 

In December 2024, the Company issued convertible notes payable to three investors in exchange for $650,000. During the year ended December 31, 2025, the Company issued 0% interest convertible notes payable to three investors in exchange for $290,000. convertible notes mature six months following that date of issuance and do not accrue interest. The notes are convertible into common shares as follows: (i) on the next equity financing conversion: the principal balance on each note will convert into shares upon the closing of the next equity financing. The number of conversion shares the Company issues upon such conversion will equal the quotient obtained by dividing (x) the outstanding principal balance under each converting note on the closing date of the next equity financing by (y) the applicable conversion price of the product of (x) 100% less the discount of 25% and (y) the lowest per share purchase price of the equity securities issued in the next equity financing; and/or (ii) corporate transaction conversion: at the closing of a major corporate transaction, the note will convert into that number of conversion shares equal to the quotient obtained by dividing (x) the outstanding principal balance of such note on the closing of such corporate transaction by (y) the applicable conversion price of the product of (x) 100% less the discount of 25% and (y) the volume weighted average trading price on the date that is ten days immediately prior to the closing date of the corporate transaction; and/or (iii) at any time on or after the maturity date, each note will convert into that number of conversion shares equal to the quotient obtained by dividing (x) the outstanding principal balance of the note on the date of such conversion by (y) the applicable conversion price of the product of (x) 100% less the discount of 25% and (y) the volume weighted average trading price on the date that is ten days immediately prior to the maturity date.

 

During the period ended March 31, 2026, the Company and four noteholders amended the terms of the convertible note agreements to retroactively accrue interest on their notes from the effective date of the agreements on a rate of 10%. During the period ended March 31, 2026, the Company recorded and accrued interest expense on the convertible notes in the amount of $16,027.

 

Company evaluated the conversion feature and determined that no embedded derivative liability existed on the issuance dates of the convertible notes. As of March 31, 2026 and December 31, 2025, the convertible notes payable principal balance was $940,000 and $940,000, respectively, and the accrued interest was $16,027 and $0, respectively. The Company calculated imputed interest on the zero percent convertible notes using an interest rate of 14% and recorded to additional paid-in-capital. As of March 31, 2026 and December 31, 2025, the Company recorded imputed interest of $27,309 and $119,040, respectively.

 

The Company evaluated the conversion feature and determined that, since the conversion price is fixed, no embedded derivative liability existed as of March 31, 2026. As March 31, 2026, the matured convertible notes would potentially be converted into 5,538,201 common shares.

 

On November 3, 2025, the Company entered into a Convertible Notes Agreement and a Warrant Purchase Agreements (the “Purchase Agreements”), dated as of October 31, 2025, with two investors (the “Holders”) for their purchase of (i) 14% convertible secured promissory notes of the Company in the aggregate original principal amount of $2,000,000 payable on October 31, 2028 (the “Notes”) with a fixed conversion price of $0.08 and (ii) 5-year warrants to purchase 6,000,000 shares of the Company’s common stock at an exercise price of $0.08. The proceeds are to used to repay all amounts outstanding under those certain 14% secured promissory notes and credit card balances to the former President of the Company in the amounts of $917,966 and $408,486, respectively. The remainder of the proceeds were used for working capital and general corporate purposes. The Company’s obligations under the Notes are secured by a security interest in certain property granted by the Company for the benefit of Holders pursuant to the terms of a Security Agreement dated October 31, 2025, between the Company and the Holders and a Patent Security Agreement dated October 31, 2025, between the Company and Holders.

 

On February 11, 2026, the Company entered into two Promissory Note Agreements (the “Additional Notes”) with the Holders for an additional $200,000. The interest on the promissory note shall equal to 125,000 shares of common stock of the Company for each note. Both the principal balance and the shares are payable on February 26, 2026. Per the agreement, If the loans were note repaid when matured, the Company will issue an additional 125,000 shares of common stock for each note and 125,000 shares every three months thereafter.

 

13

 

 

On March 17, 2026, the Company entered into a First Amendment to Note and Warrant Purchase Agreement (the “Amendment” or “Amended and Restated Note”) with the Holders. Pursuant to the Amended and Restated Note, the Company and the Holders combined the Existing Notes and the Additional Notes in their entirety under the terms of the Amended and Restated Note. Under the Amended and Restated Note, the maturity date of the Existing Notes was amended on March 26, 2026.

 

The Company recognized amortization on the debt discount of $612,338 during the period ended March 31, 2026. As of March 31, 2026 and December 31, 2025, the principal balance of the notes was $2,200,000 and $2,000,000. As of March 31, 2026 The unamortized debt discount was $0.

 

   As of March 31, 2026   As of December 31, 2025 
         
Convertible notes payable  $3,140,000   $2,327,612 
Total convertible notes payable   3,140,000    2,327,612 
Less: current portion   (3,140,000)   (940,000)
Long term convertible notes payable, net of current  $-   $1,387,612 

 

Note 6. Promissory Notes

 

On September 11, 2025, the Company entered into a Promissory Note for a principal amount of $353,050 with the Company receiving cash proceeds of $300,000. The Company recognized debt discount of $53,050 at the issuance of the notes. The note matures on August 30, 2026, and bears a one-time interest of 12% or $42,366. Any amount of principal or interest which is not paid when due shall bear interest at the rate of 22% per annum from the due date. Additionally, in the event of default, the holder may convert all or any part of the outstanding and unpaid amount of this note into shares of Company’s common stock with a discount rate of 35% on the lowest trading price of the common stock during the ten trading days prior to the conversion date.

 

During the period ended March 31, 2026, the Company repaid $172,995 of the principal balance The Company recognized amortization on the debt discount of $13,263 during the period ended March 31, 2026. As of March 31, 2026 and December 31, 2025, the principal balance of the note was $180,056 and $353,050.

 

On October 13, 2025, the Company entered into a Promissory Note for a principal amount of $76,550 with the Company receiving cash proceeds of $70,000. The Company recognized debt discount of $18,550 at the issuance of the notes. The note matures on August 15, 2026 and bears a one-time interest of 15% or $13,282. Any amount of principal or interest which is not paid when due shall bear interest at the rate of 22% per annum from the due date. Additionally, in the event of default, the holder may convert all or any part of the outstanding and unpaid amount of this note into shares of Company’s common stock with a discount rate of 35% on the lowest trading price of the common stock during the ten trading days prior to the conversion date.

 

During the period ended March 31, 2026, the Company repaid $14,087 of the principal balance The Company recognized amortization on the debt discount of $5,565 during the period ended March 31, 2026. As of March 31, 2026 and December 31, 2025, the principal balance of the note was $62,463 and $76,550.

 

On March 26, 2026, the Company entered Secured Promissory Note Agreements with two investors for their purchase of (i) 14% secured promissory notes of the Company in the aggregate original principal amount of $700,000 payable on April 17, 2026 and (ii) 5-year warrants to purchase 3,300,000 shares of the Company’s common stock at an exercise price of $0.08. The proceeds were paid directly to Rowland Day as part of the Stock Purchase Agreement. Should the Company default on repayment for the note in full by the maturity date, the Common shall issue to the holders a total of 8,750,000 shares of the Company’s common stock. The Company’s obligations under the Notes are secured by a security interest in certain property granted by the Company for the benefit of Holders pursuant to the terms of a Security Agreement dated October 31, 2025, between the Company and the Holders and a Patent Security Agreement dated October 31, 2025, between the Company and Holders. The warrants had a relative fair value of $252,834, which was recorded as a discount on the note.

 

14

 

 

The Company recognized amortization on the debt discount of $57,462 during the period ended March 31, 2026 on the promissory notes. As of March 31, 2026, the principal balance of the note was $700,000.

 

   As of March 31, 2026   As of December 31, 2025 
         
Promissory notes payable, net  $716,695   $380,321 
Total Promissory notes payable, net   716,695    380,321 
Less: current portion   (716,695)   (380,321)
Long term Promissory notes payable, net of current  $-   $- 

 

As of March 31, 2026, the unamortized debt discount was $225,823. As of December 31, 2025, the Company had unamortized debt discount of $49,279.

 

Note 7. Equity

 

The Company is currently authorized to issue up to 500,000,000 shares of common stock with a par value of $0.001. In addition, The Company is authorized to issue 50,000,000 shares of preferred stock with a par value of $0.001. The specific rights of the preferred stock, when so designated, shall be determined by the board of directors.

 

Common Stock

 

As of March 31, 2026 and December 31, 2025, there were 38,890,943 and 38,890,943 shares issued and outstanding, respectively.

 

Preferred Stock

 

Series A Convertible Preferred Stock

 

Our board of directors designated 2,068 shares of our preferred stock as Series A Convertible Preferred Stock (“Series A”) with a par value of $0.001. Series A has liquidation and dividend preferences. Each share of Series A has voting rights equal to the amount of shares of common stock into which the Series A is convertible. Each share of Series A is convertible on a 1 to 1.25 common share basis. As of each of March 31, 2026 and December 31, 2025, there were 2,068 shares of Series A issued and outstanding.

 

Series B-1 Convertible Preferred Stock

 

Our board of directors designated 8,619,420 shares of our preferred stock as Series B-1 Convertible Preferred Stock (“Series B-1”) with a par value of $0.001. Series B-1 has liquidation and dividend preferences. Each share of Series B-1 has voting rights 3.2x (times) that of the number of votes that is equal to the number of common stock into which the Series B-1 are convertible. Each share of Series B-1 is convertible on a 1 to 11 common share basis. On September 30, 2023, the Articles of Incorporation of the Company were amended to remove the redemption right of the Series B-1. The Company’s Articles of Incorporation require 51% of the outstanding votes of the Series B-1 to amend or repeal any incorporation documents that would alter the rights or preferences of Series B-1, alter the authorized number of shares of the series, create or issue any classes of preferred stock senior to the Series B-1, amend the company’s bylaws, or enter into a transaction that would result in a change in control. As of March 31, 2026 and December 31, 2025, there are 8,619,420 shares of Series B-1 issued and outstanding.

 

Effective October 31, 2025, Rowland W. Day II resigned from his positions as President, Chief Financial Officer, Secretary, Chief Legal Officer, and as a member of the Board of Directors of the Company. In connection with his resignation, the Company agreed to enter into a Stock Repurchase Agreement providing for repurchase by the Company from the Trust of up to 4,309,710 shares of the Company’s Series B-1 Preferred Stock and 307,647 shares of common stock, at per-share prices ranging from $0.605-$0.66 for the preferred shares and $0.055-$0.06 for the common shares, depending on the repurchase date.

 

On March 26, 2026, the Company entered into an amendment to the Stock Repurchase Agreement pursuant to which the Expiration Date was extended to April 10, 2026. As part of the extension of the settlement date, the Company is to pay an additional $100,000 to Rowland as an extension fee. During the period ended March 31, 2026, the Company accrued the $100,000 extension fee and paid $150,000 as a deposit on the stock re-purchase to Rowland. Additionally, $700,000 was wire directly by the noteholder to Rowland as a deposit on the stock re-purchase. As of March 31, 2026, $950,000 was recorded as Series B-1 convertible Preferred shares liability on the statement of stockholder’s equity.

 

15

 

 

On March 9, 2026, the board of directors approved the issuance of 800,000 share of Series B-1 Convertible Preferred Stock to Mr. Leal as a bonus. The 800,000 shares of Series B-1 convertible preferred stock valued at the at-converted value of $0.13 per share with a fair value of $1,129,920. As of March 31, 2026, the Series B-1 convertible Preferred shares were not issued to the equity holders and as such, the shares were recorded as Series B-1 convertible Preferred liability on the statement of stockholder’s equity.

 

Series B-2 Convertible Preferred Stock

 

Our board of directors designated 3,107,438 shares of our preferred stock as Series B-2 Convertible Preferred Stock (“Series B-2”) with a par value of $0.001. On May 1, 2023, the Articles of Incorporation of the Company were amended such that no Series B-2 shares are authorized. Series B-2 have no liquidation or dividend preferences. Each share of Series B-2 has voting rights equal to the amount of shares of common stock the Series B-2 is convertible to and is convertible on a 1 to 1 common share basis and shall automatically be converted into common shares up the Public Offering Closing. As of March 31, 2026 and December 31, 2025, there are no shares of Series B-2 issued and outstanding.

 

Common Stock Liability

 

Common stock to be issued for cash

 

During the period ended March 31, 2026, the Company granted the issuance of 4,722,224 shares of common stock for $650,000 cash. As of March 31, 2026, $50,000 of the proceeds was recorded as subscription receivable. As of March 31, 2026, the common shares were not issued to the equity holders and as such, the common shares were recorded as common stock liability on the statement of stockholder’s equity.

 

During the period ended March 31, 2026, total amount of shares payable and total value recorded as common stock liability issued for cash was 4,722,224 and $650,000, respectively.

 

Common stock to be issued for interest

 

During the period ended March 31, 2026, the Company granted the issuance of 516,000 shares of common stock in lieu of interest on convertible and promissory notes with a fair value of $81,364. As of March 31, 2026, the common shares were not issued to the equity holders and as such, the common shares were recorded as common stock liability on the statement of stockholder’s equity.

 

During the period ended March 31, 2026, total amount of shares payable and total value recorded as common stock liability issued for interest on notes was 516,000 and $81,364, respectively.

 

Common stock to be issued for accounts payable settlement

 

During the period ended March 31, 2026, the Company granted the issuance of 100,000 shares of common stock to settle an accounts payable balance with a fair value of $10,696. The Company recorded a net gain on the settlement of $5,304. As of March 31, 2026, the common shares were not issued to the equity holders and as such, the common shares were recorded as common stock liability on the statement of stockholder’s equity.

 

During the period ended March 31, 2026, total amount of shares payable and total value recorded as common stock liability issued for accounts payable settlement was 100,000 and $10,696, respectively.

 

Common stock to be issued for service

 

During the period ended March 31, 2026, the Company granted the issuance of 40,000 shares to a consultant for service rendered during the period. The shares had a fair value of $5,528, which was recorded as stock-based compensation during the period ended March 31, 2026. As of March 31, 2026, the common shares were not issued to the equity holders and as such, the common shares were recorded as common stock liability on the statement of stockholder’s equity.

 

During the period ended March 31, 2026, the Company entered into several consultant agreements where the Company granted the issuance of 1,110,238 common shares to the consultant. The shares had a fair value of $181,993, which was recorded as stock-based compensation during the period ended March 31, 2026. As of March 31, 2026, the common shares were not issued to the equity holders and as such, the common shares were recorded as common stock liability on the statement of stockholder’s equity.

 

16

 

 

On January 1, 2026, the Company entered into a consultant agreement where the consultant will receive 10,000 common shares on a monthly basis beginning on the effective date of the agreement. During the period ended March 31, 2026, the Company granted the issuance of 30,000 common shares to the consultant. The shares had a fair value of $4,509, which was recorded as stock-based compensation during the period ended March 31, 2026. As of March 31, 2026, the common shares were not issued to the equity holders and as such, the common shares were recorded as common stock liability on the statement of stockholder’s equity.

 

On December 18, 2025, the Company entered into a six month term consultant agreement where the consultant will receive 7,000 common shares on a monthly basis beginning on the effective date of the agreement. During the period ended March 31, 2026, the Company granted the issuance of 21,000 common shares to the consultant. The shares had a fair value of $3,156, which was recorded as stock-based compensation during the period ended March 31, 2026. As of March 31, 2026, the common shares were not issued to the equity holders and as such, the common shares were recorded as common stock liability on the statement of stockholder’s equity.

 

On August 1, 2025, the Company entered into a consultant agreement where the consultant will receive 7,000 common shares on a monthly basis beginning on the effective date of the agreement. On December 15,2025, the Company entered into an amendment to the consultant agreement to increase the number of monthly common shares to 14,000 common shares per month beginning on January 1, 2026. In 2025, the Company granted the issuance of 35,000 common shares to the consultant. During the period ended March 31, 2026, the Company granted the issuance of 42,000 common shares to the consultant. The shares had a fair value of $6,313, which was recorded as stock-based compensation during the period ended March 31, 2026. As of March 31, 2026, the common shares were not issued to the equity holders and as such, the common shares were recorded as common stock liability on the statement of stockholder’s equity.

 

On August 1, 2025, the Company entered into a consultant agreement where the consultant will receive 7,000 common shares on a monthly basis beginning on the effective date of the agreement. In 2025, the Company granted the issuance of 35,000 common shares to the consultant. During the period ended March 31, 2026, the Company granted the issuance of 21,000 common shares to the consultant. The shares had a fair value of $3,156, which was recorded as stock-based compensation during the period ended March 31, 2026. As of March 31, 2026, the common shares were not issued to the equity holders and as such, the common shares were recorded as common stock liability on the statement of stockholder’s equity.

 

During the period ended March 31, 2026, total amount of shares payable and total value recorded as common stock liability issued for service was 1,264,238 and $204,656, respectively.

 

As of March 31, 2026, the total common stock liability for common stock and vested restricted stock was 8,830,462 shares of common stock.

 

Restricted Common Stock

 

On March 30, 2026, the Company granted the issuance of 323,334 restricted common shares to an advisor. 83,334 restricted common shares vest immediately and the remaining balance vests in twelve months equal instalments. The restricted common shares had a fair value of $43,973. $11,332 was recognized as stock-based compensation during the period ended of March 31, 2026. As of March 31, 2026, the 83,334 restricted common shares were fully vested. As of March 31, 2026, the common shares were not issued to the equity holders and as such, the common shares were recorded as common stock liability on the statement of stockholder’s equity.

 

On November 10, 2025, the Company entered into a service agreement where the Company will grant the issuance of 40,000 restricted common shares to the advisor on or before January 18, 2026. The Company granted the issuance of the restricted common shares on December 12, 2025. The restricted common shares were granted with a six month restriction period. The restricted common shares had a fair value of $9,196. The Company recognized $4,598 as stock-based compensation during the period ended March 31, 2026. As of March 31, 2026, 0 restricted common shares were vested.

 

On October 1, 2025, the Company granted the issuance of 120,000 restricted common shares to an advisor. The restricted common shares vest in twelve months equal instalments. The restricted common shares had a fair value of $32,280. The Company recognized $8,070 as stock-based compensation during the period ended March 31, 2026. As of March 31, 2026, 60,000 restricted common shares were vested. As of March 31, 2026, the common shares were not issued to the equity holders and as such, the common shares were recorded as common stock liability on the statement of stockholder’s equity.

 

17

 

 

On December 1, 2024, the Company granted the issuance of 300,000 restricted common shares to an advisor. The restricted common shares vest in twelve months equal instalments. The restricted common shares had a fair value of $141,000, of which was recognized as stock-based compensation in 2025. As of March 31, 2026, the 300,000 restricted common shares were fully vested. As of March 31, 2026, the common shares were not issued to the equity holders and as such, the common shares were recorded as common stock liability on the statement of stockholder’s equity.

 

Stock Warrants

 

During the period ended March 31, 2026, the Company issued 3,300,000 common stock warrants with exercise price of $0.08 in conjunction with convertible secured promissory notes agreements. The warrants had a relative fair value of $252,834, which was recorded as a discount on the note. The relative fair value of the warrants was estimated using a black-scholes model with the following assumptions:

 

   Period Ended 
   March 31, 2026 
Fair value of common stock on measurement date  $0.12 per share 
Risk free interest rate (1)   4.08%
Volatility (2)   302.35%
Dividend yield (3)   0%
Expected term (in years)   5.00 years 

 

(1) The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date.
(2) The trading volatility was determined by calculating the volatility of the Company’s peer group.
(3) The Company does not expect to pay a dividend in the foreseeable future.

 

The following table summarizes the stock warrant activity for the three months ended March 31, 2026:

 

   Warrants  

Weighted-Average

Exercise Price

Per Share

 
Outstanding, December 31, 2025   6,350,000   $0.15 
Granted   3,300,000    0.08 
Exercised        
Forfeited        
Expired        
Outstanding, March 31, 2026   9,650,000   $0.12 

 

As of March 31, 2026 the outstanding and exercisable warrants have a weighted average remaining term of 4.29 with no intrinsic value.

 

18

 

 

Stock Options

 

On February 23, 2026, the Company issued 450,000 options to employees. The options issued have a one-year term at an exercise price of $0.18. The options issued to the employees vest immediately on the date of issuance. The total fair value of these option grants at issuance was $15,988. The Company valued the stock options using the Black-Scholes model with the following key assumptions:

 

   Period Ended 
   March 31, 2026 
Fair value of common stock on measurement date  $0.16 per share 
Risk free interest rate (1)   3.50%
Volatility (2)   67.73%
Dividend yield (3)   0%
Expected term (in years)   0.9 years 

 

(1) The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date.
(2) The trading volatility was determined by calculating the volatility of the Company’s peer group.
(3) The Company does not expect to pay a dividend in the foreseeable future.

 

During the three months ended March 31, 2026, the Company recognized $106,555 of expense related to outstanding stock options.

 

The following table summarizes the stock option activity for the three months ended March 31, 2026:

 

   Options  

Weighted-Average

Exercise Price

Per Share

 
Outstanding, December 31, 2025   5,465,000   $0.41 
Granted   450,000    0.18 
Exercised        
Forfeited   (550,000)   0.51 
Expired        
Outstanding, March 31, 2026   5,365,000   $0.38 
Exercisable, March 31, 2026   3,113,750   $0.36 

 

As of March 31, 2026, the outstanding and exercisable options have a weighted average remaining term of 3.87 with an intrinsic value of $0.

 

Note 8: Commitments

 

In December 2024, The Company entered into an employment agreement with Mr. Leal, of which will become effective as of the effective date of the registration statement on Form S-1 in connection with the Company’s planned public offering of its shares. Pursuant to the employment agreements, Mr. Leal has agreed to serve as Chief Executive Officer and as a Director for five years from the effective date in consideration for an annualized salary of $300,000, payable in regular instalments in accordance with the usual payment practices of the Company. The employment agreements contemplate annual bonus awards based on the achievement of performance objectives and targets established annually by the Board of Directors and possible additional bonuses for services and results achieved by Mr. Leal.

 

On July 22, 2025, the Company entered into an Independent Software Vendor Program Agreement (the “Agreement”) with Five9, Inc. (“Five9”), a Delaware corporation. Five9 is a leading provider of intelligent cloud software and applications for contact centers. Pursuant to the Agreement, Five9 granted the Company a non-exclusive, worldwide, royalty-free, non-sublicensable and non-transferable license to access the Five9 developer account with the purpose of integrating the Company’s products and services and becoming an accredited vendor under Five9’s ISV program. The Company has agreed to pay a non-refundable ISV Program participation fee to Five9 for the initial one-year term of the Agreement and for each one-year renewal term thereafter. Further, each party to the Agreement may receive referral fees from the other party for the referral of prospective customers.

 

19

 

 

On August 22, 2025, the Company entered into a Genesys AppFoundery ISV Partner Agreement with Genesys Cloud Services, Inc. (“Genesys”), a California corporation. Genesys manages the Genesys AppFoundry, a marketplace of solutions that offers Genesys customers a curated selection of integrations and applications. The agreement governs the Company’s non-exclusive participation as an AppFoundry ISV Partner in the Genesys AppFoundry Program. The Company has agreed to pay a non-refundable revenue share to Genesys during the term of the Agreement based on a percentage of the revenue invoiced by the Company or Genesys in connection with the sale of the Company’s software through the AppFoundry marketplace. The agreement may be terminated by either party without cause upon ninety (90) days written notice to the other party.

 

Note 9: Subsequent Events

 

On April 8, 2026, the Company entered into a Master Reseller Agreement (the “Reseller Agreement”) for an initial term of three-years. Upon execution of the agreement, the Company received $3,000,000 as a credit balance for future service. In connection with the Reseller Agreement, the Company granted the issuance of a ten-year warrant to purchase a number of shares of common stock having a value of $3,000,000. The warrant amount will be based on the day volume weighted average price of the common stock during the 30-day period ending on the day prior to the execution of the warrant.

 

As of April 10, 2026, the Company purchased 4,166,667 shares of the Company’s Series B-1 Preferred Stock held by Rowland at a price of $0.66 per Series B-1 Preferred share for a total cash consideration of $2,850,000.

 

On April 7, 2026, the Company defaulted on the March 26, 2026 Secured Promissory Notes. The Company granted the issuance of 8,750,000 common stock shares to the holders for failure to pay the principal and accrued interest on the maturity date.

 

20

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the financial statements and the related notes appearing elsewhere in this Form 10-Q. This discussion contains forward-looking statements reflecting our current expectations that involve risks and uncertainties. See Item 1A. “Risk Factors” of our Form 10-K for the year ended December 31, 2025, available on the Security and Exchange Commission’s (“SEC”) EDGAR website at www.sec.gov, for a discussion of the uncertainties, risks and assumptions associated with these statements. Actual results and the timing of events could differ materially from those discussed in our forward-looking statements as a result of many factors, including those set forth under “Risk Factors” and elsewhere in this Form 10-Q.

 

Overview

 

The Company operates to develop artificial intelligence products that enable companies and individuals to reach their highest potential by eliminating language barriers in daily communications by providing high-quality, accurate, and efficient interpretation and translation services using natural language processing (NLP) technology. The Company’s focus is on developing a proprietary architecture that is faster and more accurate than any other company, with a commitment to providing superior quality services to its customers. The Company intends to serve a wide variety of markets and customers and will be focused on becoming a leader in the creation of pragmatic products for the interpretation and translation industry.

 

Business Summary

 

We develop and market artificial intelligence products that eliminate language barriers in daily communications by providing high-quality, accurate, and efficient interpretation and translation services using natural language processing (NLP) technology. Our proprietary AI and machine learning architecture enable seamless translation and transcription of spoken and written words in seconds across multiple languages. Our VerbumSuite platform facilitates fluid and effective communication among individuals regardless of linguistic differences. With support for real-time conversations over-the-phone, virtual meetings, and online chats in over 140 languages and dialects, Verbum is reshaping how organizations, educational institutions, and customer service centers connect and collaborate. The Company develops and markets artificial intelligence products that eliminate language barriers in daily communications by providing high-quality, accurate, and efficient interpretation and translation services using natural language processing (NLP) technology. Our focus is on developing a proprietary architecture that is faster and more accurate than any other company, with a commitment to providing superior quality services to its customers. We intend to serve a wide variety of markets and customers and are focused on becoming a leader in the creation of products for the interpretation, translation, and transcription industries. Driven by a vision to create a more understanding world and revolutionize global communication, we are committed to solving complex problems with practical solutions. We recognize that artificial intelligence has the potential to turn good decisions into great ones, and we strive to harness this potential to drive positive change across industries.

 

Our Products

 

Our current VerbumSuite products described in detail below are built on our proprietary and patented systems and methods for substantially real-time speech, transcription, and translation technology. We are also developing additional proprietary products and features to expand the service capabilities built on our core technological foundation.

 

  Verbum. Verbum supports real time web-based conversations, discussions, meetings, and online chats in 140 languages, enabling fluent and effective communication among individuals that do not speak the same language. This product is distributed through our online platform, direct sales to businesses and organizations, and we are attempting to develop partnerships with existing video conferencing providers. The competitive position is against other video conferencing providers that also offer live interpretation services, such as Microsoft Teams, Zoom and Google Meet. We believe our main competitors are organizations that supply human interpreters which can be ten times more expensive than our Verbum product. The Verbum product is available to customers at a wholesale price of $0.30 to $0.36 per minute, as compared to human interpreters, which can range from $45.00 to $150.00 per hour, or $1.25 to $3.00 per minute.(1) The primary market for our Verbum product is for organizations or individuals that require real-time interpretation services.

 

(1) As reported in “Medical Interpreters in Outpatient Practice”, available at https://pmc.ncbi.nlm.nih.gov/articles/PMC5758324/.

 

VerbumOnSiteTM Real Time Translation Powered by AI

 

  Multilingual Events - unlocks the power of seamless communication at live events through real-time translation and captioning services. Attendees can effortlessly scan a QR code to access real-time captions in over 140 languages directly on their phones.
  Ease of Integration - integrates into the event setup, ensuring a smooth and hassle-free experience for organizers and attendees. User-friendly, web-based design and compatibility incorporates powerful multilingual features without technical complexities.

 

21

 

 

  Inclusive Communication - committed to breaking language barriers and making events accessible to all such as for those with hearing disabilities. Our solution provides real-time, multilingual closed captions, ensuring full engagement in conversations and presentations and fostering an inclusive event experience.
  Currently available for use in live events requiring multilingual support.

 

VerbumCallTM – AI-Powered Over-the-Phone Interpretation with No App or Internet Required

 

  Multilingual Calls - unlocks the power of seamless communication over the phone; similar to having a translator readily available in 140+ languages. VerbumCall transforms any mobile device into a personal translator without the need for internet connection or additional applications.
  Ease of Integration - integrates into the users current systems incorporating powerful multilingual calls without technical complexities.
  Scalable & Confidential - offers a scalable solution that adapts to the users business needs, whether making one call or thousands of calls. Our AI-powered conversations enable calls to be private and secure, ensuring business communications are confidential and protected.
  Currently available for integration with major Contract Center as a Service (CCaaS) providers.

 

VerbumTM for Microstoft Teams – AI Translation for Multilingual Meetings

 

  Enhances the Microsoft Teams experience by facilitating multilingual groups to come together in meetings. Enables collaborators from all over the world to work together without language barriers. Each attendee chooses the language that they will be speaking in and the language in which they want to see captions and chat. As each person speaks in their preferred language from a list of 95+ languages, it is translated in near real-time for the rest of the group.
  When a user selects their preferred language, it does not impact the other users in the meeting. The system allows each user to understand and be understood using their preferred language.
  Translates chat messages into 3 selected languages in near real-time to allow flow of communication.
  Enables a transcript function allowing the user to upload documents that can be translated into 95+ languages and shared with the whole team.
  No formal legal or commercial agreement is required with Microsoft for the operation of this product within Microsoft Teams. The Company fully complies with Microsoft’s comprehensive development, publishing, and certification standards to ensure functionality, security and accessibility.
  Integration with Microsoft Teams is achieved through Microsoft Teams APIs and compliance with a detailed manifest that undergoes thorough third-party review. The manifest governs Verbum’s features and ensures secure, real-time multilingual translation capabilities, including captions and chat translations for over 120 languages. Verbum interacts with Microsoft Teams by processing real-time meeting audio and chat data (with user permission) to deliver high-accuracy, AI-powered translations directly within the Microsoft Teams interface.
  Fully operational and available to users.

 

  Verbum SDK. Verbum Software Developer Kit allows software programmers, potential channel partners, and corporate development teams to integrate our powerful multilingual communications platform Verbum™ — into new or existing Software-as-a-Service applications and/or client/server programs, helping them remove communications barriers for multinational organizations and/or those serving customers who speak/read different languages. This product may be distributed through partnerships with software developers or through direct sales to businesses and organizations that require interpretation services for their software. The competitive position would be against other software development kit providers that also offer interpretation services, such as Microsoft Azure or Amazon Translate. The expected market for this product is software developers and businesses that require interpretation services for their software applications.

 

22

 

 

Components of Our Results of Operations

 

Net Revenue

 

We currently derive our revenue primarily from the sale of our products. We expect our net revenue to increase in the foreseeable future as we add new customers and offer additional products, though net revenue may fluctuate from quarter to quarter due to a variety of factors, including the pace of research and development and completion of additional products.

 

Operating Expenses

 

Operating expenses consist primarily of research and development, salaries and benefits, infrastructure and equipment, professional services and distribution and delivery.

 

  Research and Development: Developing and maintaining the proprietary NLP technology and architecture will be a significant future expense for the Company. This will include expenses related to hiring and retaining top talent, conducting research and development, and investing in technology infrastructure and equipment.

 

  Salaries and Benefits: The Company plans to invest in hiring and retaining additional employees to perform various functions, such as software development, customer support, sales, and administration. This will include salaries, benefits, and other employee-related expenses.

 

  Infrastructure and Equipment: The Company will invest in technology infrastructure and equipment to support its software development and distribution operations. This will include expenses related to servers, software licenses, hardware, and office equipment.

 

  Professional Services: Depending on the Company’s needs, it may need to engage professional services such as legal, accounting, or consulting services, which would be an expense for the Company.

 

  Distribution and Delivery: The Company will need to invest in distribution and delivery methods for its products, such as software updates, shipping, or online delivery. This will include expenses related to logistics, software licensing, or server maintenance.

 

Total Other Expense

 

Other expenses consist primarily of interest expense. It also includes any gains and loss attributable to the changes in fair market value from the derivative liabilities associated with the issuance of convertible notes.

 

Results of Operations for the Three Months Ended March 31, 2026 and 2025

 

The following table summarizes selected items from the statement of operations for the three months ended March 31, 2026 and 2025, respectively.

 

   Three months
ended
   Three months
ended
   Increase/ 
   March 31, 2026   March 31, 2025   (Decrease) 
             
Revenue  $180,117   $128,518   $51,599 
Cost of Revenue   65,560    -    65,560 
Gross Profit   114,557    128,518    (13,961)
                
Operating expenses:               
Research and development   406,311    349,586    56,725 
General and administrative   1,937,753    481,320    1,456,433 
Advertising and marketing   2,011    8,725    (6,714)
Legal and professional   154,367    218,420    (64,053)
                
Total operating expenses   2,500,442    1,058,051    1,442,391 
                
Loss from operations   (2,385,885)   (929,533)   (1,456,352)
                
Other income (expense):               
                
Other income   5,304    -    5,304 
Interest expense   (926,373)   (24,682)   (901,691)
                
Total other expense   (921,069)   (24,682)   (896,387)
                
Net loss  $(3,306,954)  $(954,215)  $(2,352,739)

 

23

 

 

Revenue and Cost of Revenue

 

Our revenue for the three months ended March 31, 2026 was $180,117, compared to $128,518 for the three months ended March 31, 2025, an increase of $51,599. Our cost of revenue for the three months ended March 31, 2026 was $65,560, compared to $0 for the three months ended March 31, 2025, an increase of $65,560. The Company entered into several new sales and service contracts and began recognizing revenue from the new contracts during the half-end of the year ended December 31, 2025 and during the period ended March 31, 2026.

 

Operating Expenses

 

Our total operating expenses for the three months ended March 31, 2026, were $2,500,442, compared to $1,058,051for the three months ended March 31, 2025, an increase of $1,442,391. The increase in our operating expenses was primarily a result of an increase in (i) research and development expenses, from $349,586 for the three months ended March 31, 2025 to $406,311 for the three months ended March 31, 2026, (ii) general and administrative expenses, from $481,320 for the three months ended March 31, 2025 to $1,937,753 for the three months ended March 31, 2026, and (iii) legal and professional expenses, from $218,420 for the three months ended March 31, 2025 to $154,367 for the three months ended March 31, 2026, each of which were connected to management’s efforts to perform obligations related to new sales contracts, increased efforts to develop new products and improve new products and increased consulting fees related to the registration of the Company with the SEC.

 

Other Expense

 

For the three months ended March 31, 2026, other expense was $921,069. For the three months ended March 31, 2025, other expense was $24,682. Other expense increased by $896,387 was due to increased interest expense and amortization of debt discount, which was attributable to increased borrowings in 2026.

 

Net Loss

 

Net loss for the three months ended March 31, 2026, was $3,306,954, compared to $954,215 for the three months ended March 31, 2025, an increased net loss of $2,352,739. The increased net loss was primarily due to $1,442,391 of increased operating expenses.

 

Liquidity and Capital Resources

 

The following table summarizes our total current assets, liabilities and working capital as of March 31, 2026 and December 31, 2025.

 

   March 31,   December 31, 
   2026   2025 
Current Assets  $243,519   $121,937 
           
Current Liabilities  $6,319,486   $3,044,251 
           
Working Capital (Deficit)  $(6,075,967)  $(2,922,314)

 

24

 

 

As of March 31, 2026, we had working capital deficit of $6,075,967. We have incurred net losses since our inception and we anticipate net losses and negative operating cash flows for the near future and we may not be profitable or realize growth in the value of our assets. We have incurred net losses since our inception and we anticipate net losses and negative operating cash flows for the near future and we may not be profitable or realize growth in the value of our assets. To date, our primary sources of capital have been cash generated from common stock sales and debt financing.

 

As of December 31, 2025, the Company had not yet achieved profitable operations and expects to incur further losses in the development of its business, all of which raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon its ability to generate future profitable operations and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management is seeking to obtain additional funds by equity financing and or related party advances, however, there is no assurance of additional funding being available. If we fail to increase our revenue, raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue our operations or the development and commercialization of one or more of our products. Where the anticipated offering is successful, we may decide to raise additional financing, in addition to the net proceeds from this offering, to support further growth of our operations. Where the anticipated offering is unsuccessful, we expect to use proceeds from the issuance of equity, debt financings, or other capital transactions to fund our operations and satisfy our liquidity requirements.

 

We believe our ability to achieve commercial success and continued growth will be dependent upon our ability to sell our products and our continued access to capital either through sales of our equity or cash generated from operations. We will attempt to obtain additional capital through private investors; however, we have no agreements or understandings with third parties at this time in regard to investing additional monies.

 

The Company doesn’t have any plans to repurchase any of its equity or debt.

 

Cash Flow

 

Comparison of the Three Months Ended March 31, 2026 and the Three Months Ended March 31, 2025

 

The following table sets forth the primary sources and uses of cash for the periods presented below:

 

   Three Months Ended 
   March 31, 
   2026   2025 
Net cash used in operating activities  $(32,378)  $(616,575)
Net cash provided by financing activities   87,918    443,000 
           
Net change in cash  $55,540   $(173,575)

 

Net Cash Used in Operating Activities

 

Net cash used in operating activities was $32,378 for the three months ended March 31, 2026, compared to $616,575 for the three months ended March 31, 2025, a decrease of $584,197. The change was primarily attributable to changes in equity related liabilities, amortization expense, accounts receivable, accounts payable and deferred revenue.

 

25

 

 

Net Cash Provided by Financing Activities

 

Net cash provided by financing activities was $87,918 for the three months ended March 31, 2026, compared to $443,000 for the three months ended March 31, 2025, an decrease of $355,082. Our decrease cash provided by financing activities was primarily attributable to our decrease in proceeds from debt financing and increased payments on debt financing during the period ended March 31, 2026.

 

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

 

Our financial results are affected by the selection and application of accounting policies and methods. In the three-month period ended March 31, 2026, there were no changes to the application of critical accounting policies previously disclosed in the Registration Statement.

  

CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS

 

This report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements in this report, other than statements of historical fact, are “forward-looking statements” for purposes of these provisions, including any projections of earnings, revenues or other financial items, any statements of the plans and objectives of our management for future operations, any statements concerning proposed new products or services, any statements regarding the integration, development or commercialization of the business or any assets acquired from other parties, any statements regarding future economic conditions or performance, and any statements of assumptions underlying any of the foregoing. In some cases, forward-looking statements can be identified by the use of terminology such as “may,” “will,” “expects,” “plans,” “anticipates,” “intends,” “seeks,” “believes,” “estimates,” “potential,” “forecasts,” “continue,” or other forms of these words or similar words or expressions, or the negative thereof or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, there can be no assurance that such expectations or any of the forward-looking statements will prove to be correct, and actual results will likely differ, and could differ materially, from those projected or assumed in the forward-looking statements. Investors are cautioned not to unduly rely on any such forward-looking statements.

 

All subsequent forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. Our actual results will likely differ, and may differ materially, from anticipated results. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results. All forward-looking statements included in this report are made as of the date hereof and are based on information available to us as of such date. We assume no obligation to update any forward-looking statement. If we do update or correct one or more forward-looking statements, investors and others should not conclude that we will make additional updates or corrections.

 

NOTICE REGARDING TRADEMARKS

 

This report includes trademarks, tradenames and service marks that are our property or the property of others. Solely for convenience, such trademarks and tradenames sometimes appear without any “™” or “®” symbol. However, failure to include such symbols is not intended to suggest, in any way, that we will not assert our rights or the rights of any applicable licensor, to these trademarks and tradenames.

 

26

 

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Our management is responsible for establishing and maintaining adequate disclosure controls and procedures for our company. Consequently, our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15 under the Exchange Act as of March 31, 2026. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. Based on that evaluation, our chief executive officer concluded that our disclosure controls and procedures are designed at a reasonable assurance level and are ineffective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

 

Based on the evaluation of our internal control over financial reporting, our management concluded that our internal control over financial reporting were not effective as of December 31, 2025 and March 31, 2026.

 

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a more than remote possibility that a misstatement of our company’s annual or interim financial statements could occur. In its assessment of the effectiveness of our internal control over financial reporting, we determined that there were control deficiencies that constituted material weaknesses which are indicative of many small companies with small staff, such as:

 

(1) inadequate segregation of duties and effective risk assessment;

 

(2) insufficient written policies and procedures for documenting all transactions with vendors;

 

(3) insufficient written policies and procedure for the approval, identification and reporting of related-party transactions;

 

(4) inadequate internal control procedures over financial reporting, resulting in non-reliance on previously issued financial statements; and

 

(5) inadequate written policies and procedures for documenting informal agreements.

 

Changes in Internal Control Over Financial Reporting

 

During the three-month period ended March 31, 2026, there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934).

 

27

 

 

PART II - OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

We are not currently party to any pending legal proceedings that we believe would, individually or in the aggregate, have a material adverse effect on our financial condition, cash flows or results of operations.

 

ITEM 1A. RISK FACTORS

 

As a smaller reporting company, we are not required to provide information typically disclosed under this item.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

 

None

 

ITEM 4. MINE SAFETY DISCLOSURES

 

The disclosure required by this item is not applicable.

 

ITEM 5. OTHER INFORMATION

 

During the three-month period ended March 31, 2026, no director or officer adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Regulation S-K, Item 408.

 

ITEM 6. EXHIBITS.

 

Exhibit   Description
31.1*   Certification of Chief Executive and Financial Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a)
32.1*   Certification of Chief Executive and Financial Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

* Filed herewith
** Previously filed
Indicates management contract or compensatory plan or arrangement

 

28

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registration has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Signature   Title   Date
         
/s/ Saul Leal   Chief Executive Officer   May 15, 2026
Saul Leal   (Principal Executive and Financial Officer)    

 

29

 

FAQ

How did OneMeta (ONEI) perform financially in Q1 2026?

OneMeta reported Q1 2026 revenue of $180,117, up from $128,518 a year earlier, but its net loss widened to $3,306,954 from $954,215. Operating expenses more than doubled to $2,500,442, and interest expense increased sharply, pressuring overall results.

What is OneMeta (ONEI)’s liquidity and working capital position as of March 31, 2026?

As of March 31, 2026, OneMeta had $60,124 in cash, current assets of $243,519 and current liabilities of $6,319,486. This resulted in a working capital deficit of $6,075,967, indicating a significant shortfall between near‑term obligations and liquid resources.

Why does OneMeta (ONEI) disclose substantial doubt about continuing as a going concern?

Management cites recurring losses, a Q1 2026 net loss of $3,306,954, negative operating cash flow and a $6,075,967 working capital deficit. The company has not yet achieved profitable operations and must secure additional financing or generate sufficient cash from operations to meet obligations.

What debt obligations and convertible instruments does OneMeta (ONEI) have outstanding?

At March 31, 2026, OneMeta reported $3,140,000 in convertible notes payable, $450,000 in related‑party convertible notes and $716,695 in promissory notes, alongside 9,650,000 warrants and 5,365,000 stock options, reflecting substantial leverage and potential equity dilution.

What were the key subsequent events after March 31, 2026 for OneMeta (ONEI)?

After March 31, 2026, OneMeta received a $3,000,000 prepayment under a Master Reseller Agreement, repurchased 4,166,667 Series B‑1 preferred shares for $2,850,000 cash, and defaulted on March 26, 2026 secured promissory notes, issuing 8,750,000 common shares to the noteholders.

How many shares of OneMeta (ONEI) common stock were outstanding in Q1 2026?

As of May 15, 2026, OneMeta had 38,890,943 shares of common stock outstanding. In addition, the company recorded liabilities for 8,830,462 common shares to be issued and maintained significant outstanding warrants and stock options, increasing potential future share count.